robatumumab (SCH 717454) / Merck (MSD) - LARVOL DELTA

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) (clinicaltrials.gov) - P1; N=4; Terminated; Sponsor: Merck Sharp & Dohme Corp.; Completed ➔ Terminated; Study was terminated for business reasons.

Clinical • Combination therapy • Trial termination • Genito-urinary Cancer • Kidney Cancer • Neuroblastoma • Neutropenia • Oncology • Osteosarcoma • Pediatrics • Renal Cell Carcinoma • Sarcoma • Solid Tumor • IGF1 • IGF2 • IGFBP2 • IGFBP3

A study of SCH 717454 in combination with different treatment regimens in subjects with advanced solid tumors (P04722) (clinicaltrials.gov) - P2, N=15; Completed -> Terminated

Trial terminated • Oncology

A study to determine the activity of SCH 717454 in subjects with relapsed osteosarcoma or Ewing's sarcoma (Study P04720AM3) (clinicaltrials.gov) - P2, N=249; Completed → Active, not recruiting; Completion date: Aug 2011 -> Aug 2013

Completion date • Enrollment closed • Oncology

A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer (ASCO 2011) - P04721; P2, N=67; 7 out of 41 evaluable subjects (17%) had a >20% decrease in SUVmax; 5 of the 7 had minimal decrease in SUVmax between period 1 and period 2; PR=1(2%), SD=17 (27%) and PD=39 (61%) per investigator assessment;SCH 71745 treatment was associated with marked decreases in IGFBP2 and IGF1R and with a marked increase in IGFBP3